SMART Health Cards: Vaccination & Testing Implementation Guide
1.0.0 - STU1
SMART Health Cards: Vaccination & Testing Implementation Guide
1.0.0 - STU1
SMART Health Cards: Vaccination & Testing Implementation Guide, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-shc-vaccination-ig/ and changes regularly. See the Directory of published versions
| Official URL: http://hl7.org/fhir/uv/shc-vaccination/ValueSet/immunization-all-cvx | Version: 1.0.0 | |||
| Standards status: Trial-use | Maturity Level: 4 | Computable Name: ImmunizationAllCvxValueSet | ||
Contains all CVX codes from https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx as of 2025-09-03. This list of codes will not update automatically, so please refer to this URL for the most up-to-date codes.the most up-to-date codes.
References
http://hl7.org/fhir/sid/cvx| Code | Display |
| 54 | adenovirus, type 4 |
| 55 | adenovirus, type 7 |
| 82 | adenovirus, unspecified formulation |
| 24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis |
| 19 | BCG |
| 27 | botulinum antitoxin |
| 26 | cholera, unspecified formulation |
| 29 | CMVIG |
| 56 | dengue fever tetravalent |
| 12 | diphtheria antitoxin |
| 28 | DT (pediatric) |
| 20 | DTaP |
| 106 | DTaP, 5 pertussis antigens |
| 107 | DTaP, unspecified formulation |
| 110 | DTaP-Hep B-IPV |
| 50 | DTaP-Hib |
| 120 | DTaP-Hib-IPV |
| 130 | DTaP-IPV |
| 22 | DTP-Hib |
| 102 | DTP-Hib-Hep B |
| 57 | hantavirus |
| 52 | Hep A, adult |
| 83 | Hep A, ped/adol, 2 dose |
| 84 | Hep A, ped/adol, 3 dose |
| 31 | Hep A, pediatric, unspecified formulation |
| 85 | Hep A, unspecified formulation |
| 104 | Hep A-Hep B |
| 30 | HBIG |
| 42 | Hep B, adolescent/high risk infant |
| 43 | Hep B, adult |
| 44 | Hep B, high-dosage, dialysis or IC |
| 45 | Hep B, unspecified formulation |
| 58 | Hep C |
| 59 | Hep E |
| 60 | herpes simplex 2 |
| 46 | Hib (PRP-D) |
| 47 | Hib (HbOC) |
| 48 | Hib (PRP-T) |
| 49 | Hib (PRP-OMP) |
| 17 | Hib, unspecified formulation |
| 51 | Hib-Hep B |
| 61 | HIV |
| 118 | HPV, bivalent |
| 62 | HPV, quadrivalent |
| 86 | IG |
| 87 | IGIV |
| 14 | IG, unspecified formulation |
| 111 | Influenza, live, trivalent, intranasal, PF |
| 15 | influenza, split (incl. purified surface antigen) |
| 16 | influenza, whole |
| 88 | influenza, unspecified formulation |
| 123 | influenza, H5N1-1203 |
| 10 | IPV |
| 89 | polio, unspecified formulation |
| 39 | Japanese encephalitis SC |
| 63 | Junin virus |
| 64 | leishmaniasis |
| 65 | leprosy |
| 66 | Lyme disease |
| 94 | MMRV |
| 67 | malaria |
| 68 | melanoma |
| 32 | meningococcal MPSV4 |
| 103 | meningococcal C conjugate |
| 114 | meningococcal MCV4P |
| 108 | meningococcal ACWY, unspecified formulation |
| 69 | parainfluenza-3 |
| 11 | pertussis |
| 23 | plague |
| 33 | pneumococcal polysaccharide PPV23 |
| 100 | pneumococcal conjugate PCV 7 |
| 109 | pneumococcal, unspecified formulation |
| 70 | Q fever |
| 18 | rabies, intramuscular injection |
| 40 | rabies, intradermal injection |
| 90 | rabies, unspecified formulation |
| 72 | rheumatic fever |
| 73 | Rift Valley fever |
| 34 | RIG |
| 119 | rotavirus, monovalent |
| 122 | rotavirus, unspecified formulation |
| 116 | rotavirus, pentavalent |
| 74 | rotavirus, tetravalent |
| 71 | RSV-IGIV |
| 93 | RSV-MAb |
| 38 | rubella/mumps |
| 76 | Staphylococcus bacterio lysate |
| 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed |
| 115 | Tdap |
| 35 | tetanus toxoid, adsorbed |
| 112 | tetanus toxoid, unspecified formulation |
| 77 | Tick-borne encephalitis vaccine (non-US) |
| 13 | TIG |
| 95 | TST-OT tine test |
| 96 | TST-PPD intradermal |
| 97 | TST-PPD tine test |
| 98 | TST, unspecified formulation |
| 78 | tularemia vaccine |
| 91 | typhoid, unspecified formulation |
| 25 | typhoid, oral |
| 41 | typhoid, parenteral |
| 53 | typhoid, parenteral, AKD (U.S. military) |
| 101 | typhoid, ViCPs |
| 75 | Vaccinia (smallpox, mpox), live |
| 105 | vaccinia (smallpox) diluted |
| 79 | vaccinia immune globulin |
| 21 | varicella |
| 81 | VEE, inactivated |
| 80 | VEE, live |
| 92 | VEE, unspecified formulation |
| 36 | VZIG |
| 117 | VZIG (IND) |
| 37 | yellow fever live |
| 121 | zoster live |
| 998 | no vaccine administered |
| 999 | unknown |
| 99 | RESERVED - do not use |
| 133 | Pneumococcal conjugate PCV 13 |
| 134 | Japanese Encephalitis IM |
| 137 | HPV, unspecified formulation |
| 136 | Meningococcal MCV4O |
| 135 | Influenza, high-dose, trivalent, PF |
| 131 | typhus, historical |
| 132 | DTaP-IPV-HIB-HEP B, historical |
| 128 | Novel Influenza-H1N1-09, all formulations |
| 125 | Novel Influenza-H1N1-09, nasal |
| 126 | Novel influenza-H1N1-09, preservative-free |
| 127 | Novel influenza-H1N1-09 |
| 138 | Td (adult) |
| 139 | Td(adult) unspecified formulation |
| 140 | Influenza, split virus, trivalent, PF |
| 129 | Japanese Encephalitis, unspecified formulation |
| 141 | Influenza, split virus, trivalent, preservative |
| 142 | tetanus toxoid, not adsorbed |
| 143 | Adenovirus types 4 and 7 |
| 144 | influenza, seasonal, intradermal, preservative free |
| 145 | RSV-MAb (new) |
| 146 | DTaP,IPV,Hib,HepB |
| 147 | meningococcal MCV4, unspecified formulation |
| 148 | Meningococcal C/Y-HIB PRP |
| 149 | Influenza, live, quadrivalent, intranasal |
| 150 | Influenza, split virus, quadrivalent, PF |
| 151 | influenza nasal, unspecified formulation |
| 152 | Pneumococcal Conjugate, unspecified formulation |
| 153 | Influenza, MDCK, trivalent, PF |
| 154 | Hep A, IG |
| 155 | Influenza, recombinant, trivalent, PF |
| 156 | Rho(D)-IG |
| 157 | Rho(D) -IG IM |
| 158 | Influenza, split virus, quadrivalent, preservative |
| 159 | Rho(D) - Unspecified formulation |
| 160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 |
| 801 | AS03 Adjuvant |
| 161 | Influenza, injectable,quadrivalent, preservative free, pediatric |
| 162 | meningococcal B, recombinant |
| 163 | meningococcal B, OMV |
| 164 | meningococcal B, unspecified |
| 165 | HPV9 |
| 166 | influenza, intradermal, quadrivalent, preservative free |
| 167 | meningococcal, unknown serogroups |
| 168 | Influenza, adjuvanted, trivalent, PF |
| 169 | Hep A, live attenuated |
| 170 | DTAP/IPV/HIB - non-US |
| 171 | Influenza, MDCK, quadrivalent, PF |
| 172 | cholera, WC-rBS |
| 173 | cholera, BivWC |
| 174 | cholera, live attenuated |
| 175 | Rabies - IM Diploid cell culture |
| 176 | Rabies - IM fibroblast culture |
| 177 | PCV10 |
| 178 | OPV bivalent |
| 179 | OPV ,monovalent, unspecified |
| 180 | tetanus immune globulin |
| 181 | anthrax immune globulin |
| 182 | OPV, Unspecified |
| 183 | Yellow fever vaccine live - alt |
| 184 | Yellow fever, unspecified |
| 185 | Influenza, recombinant, quadrivalent, PF |
| 186 | Influenza, MDCK, quadrivalent, preservative |
| 187 | zoster recombinant |
| 188 | zoster, unspecified formulation |
| 189 | HepB-CpG |
| 190 | Typhoid conjugate vaccine (TCV) |
| 191 | meningococcal A polysaccharide (non-US) |
| 192 | meningococcal AC polysaccharide (non-US) |
| 193 | Hep A-Hep B, pediatric/adolescent |
| 194 | Influenza, Southern Hemisphere |
| 195 | DT, IPV adsorbed |
| 196 | Td, adsorbed, preservative free, adult use, Lf unspecified |
| 197 | Influenza, high-dose, quadrivalent, PF |
| 200 | influenza, Southern Hemisphere, pediatric, preservative free |
| 201 | Influenza, Southern Hemisphere, quadrivalent, PF |
| 202 | influenza, Southern Hemisphere, quadrivalent, with preservative |
| 198 | DTP-hepB-Hib Pentavalent Non-US |
| 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) |
| 205 | Influenza, adjuvanted, quadrivalent, PF |
| 206 | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection |
| 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose |
| 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose |
| 213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED |
| 210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL |
| 212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL |
| 204 | Ebola Zaire vaccine, live, recombinant, 1mL dose |
| 214 | Ebola, unspecified |
| 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL |
| 500 | COVID-19 Non-US Vaccine, Product Unknown |
| 501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) |
| 502 | COVID-19 IV Non-US Vaccine (COVAXIN) |
| 503 | COVID-19 LAV Non-US Vaccine (COVIVAC) |
| 504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) |
| 505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) |
| 506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology |
| 507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) |
| 508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) |
| 509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) |
| 510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) |
| 511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) |
| 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF |
| 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF |
| 219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose |
| 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose |
| 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose |
| 220 | HepB recombinant, 3-antigen, Al(OH)3 |
| 221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose |
| 222 | Tick-borne encephalitis, unspecified |
| 223 | Tick-borne encephalitis, inactivated, PF, 0.25mL |
| 224 | Tick-borne encephalitis, inactivated, PF, 0.5mL |
| 225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL |
| 226 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL |
| 512 | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) |
| 513 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) |
| 514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) |
| 515 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) |
| 516 | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) |
| 517 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) |
| 227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose |
| 228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose |
| 229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose |
| 301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose |
| 300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose |
| 230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL |
| 518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) |
| 519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna |
| 520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech |
| 521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK |
| 231 | influenza, Southern Hemisphere, high-dose, quadrivalent |
| 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF |
| 304 | Respiratory syncytial virus (RSV), unspecified |
| 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF |
| 306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months |
| 307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months |
| 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL |
| 308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL |
| 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL |
| 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL |
| 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL |
| 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL |
| 315 | Respiratory syncytial virus (RSV) MAB, unspecified |
| 314 | Respiratory syncytial virus (RSV) vaccine, unspecified |
| 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF |
| 317 | Chikungunya live attenuated vaccine, 0.5 mL, PF |
| 318 | Anthrax, post-exposure prophylaxis |
| 319 | Anthrax vaccine, unspecified |
| 320 | Influenza, MDCK, trivalent, preservative |
| 321 | Influenza-avian, H5N8, monovalent, PF |
| 322 | Influenza-avian, H5N8, monovalent, preservative |
| 324 | Poliovirus, inactivated, fractional-dose (fIPV) |
| 323 | Influenza-avian, H5, unspecified formulation |
| 326 | RSV, mRNA, injectable, PF |
| 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF |
| 328 | Meningococcal oligosaccharide (MenACWY), (MenB), PF |
| 329 | Chikungunya, VLP, recombinant, 0.8 mL, PF |
| 330 | Dengue fever, unspecified |
| 331 | Influenza, Southern Hemisphere, trivalent, PF |
| 325 | Vaccinia (smallpox, mpox), unspecified |
| 332 | RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF |
| 333 | Influenza, live, trivalent, intranasal, self/caregiver admin, PF |
| 302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose |
Expansion from tx.fhir.org based on codesystem Vaccine Administered Code Set (CVX) version20250715
This value set contains 278 concepts
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |
IG © 2021+ HL7 International / Public Health. Package hl7.fhir.uv.shc-vaccination#1.0.0 based on FHIR 4.0.1. Generated 2025-09-03
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change